Study in Subjects Undergoing Complete Abdominoplasty

• ClinicalTrials.gov Identifier: NCT03789318
• Recruitment Status: Completed
• First Posted: December 28, 2018
• Results First Posted: January 13, 2022
• Last Update Posted: March 19, 2024
• Sponsor: Concentric Analgesics
• Information provided by (Responsible Party): Concentric Analgesics

Study Description

Brief Summary:

Phase 2, single center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 vs. placebo in subjects undergoing an elective C-ABD under general anesthesia supplemented with a bupivacaine hydrochloride (HCl)transverse abdominis plane (TAP) block.

Condition or disease	Intervention/treatment	Phase
Postsurgical Pain	Drug: CA-008 5 mg; Drug: Placebo; Drug: Bupivacaine Hydrochloride; Drug: Hydromorphone; Drug: Fentanyl; Drug: Acetaminophen; Drug: Oxycodone; Drug: CA-008 10 mg; Drug: CA-008 15 mg	Phase 2

Detailed Description:

This is a Phase 2, single-center, randomized, double-blind, placebo-controlled, parallel design study evaluating up to 4 ascending dose level cohorts, each evaluating a single dose of CA-008 vs. placebo injected/instilled during an elective C-ABD. Up to 72 subjects may be randomized in 4 cohorts.

For each subject, postsurgical assessments will be conducted in two parts:

• Inpatient period: starts with completion of study treatment injection (T0) and continues through 96 hours (T96h).
• Outpatient period: begins on discharge from the inpatient unit through various follow up visits to day 29 (D29)/week 4 (W4) after surgery. Note that additional follow up visits may occur at any time or even after D29/W4 to follow adverse events (AEs) to resolution or establishment of a new baseline.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 54 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Randomized, Double-blind, Placebo-Controlled Efficacy, Pharmacokinetics and Safety Study of CA-008 in Subjects Undergoing Complete Abdominoplasty
• Actual Study Start Date: December 3, 2018
• Actual Primary Completion Date: May 16, 2019
• Actual Study Completion Date: June 12, 2019

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: CA-008 5 mg (0.05 mg/mL) Cohort 1; Cohort 1 (CA-008 5 mg): the surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).	Drug: CA-008 5 mg; 5 mg CA-008 reconstituted in saline.; Other Name: Vocacapsaicin; Drug: Bupivacaine Hydrochloride; 0.25% administered pre-surgery; Drug: Hydromorphone; 0.02 mg/kg IV administered intraoperatively; Drug: Fentanyl; 100 mcg IV administered intraoperatively; Drug: Acetaminophen; 1000 mg IV administered intraoperatively; Drug: Oxycodone; 5-10 mg PO administered post-surgery
Placebo Comparator: Placebo for Cohort 1; Cohort 1: Placebo comparator is identical in appearance to the investigational product, containing the same excipients as the active comparator. The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).	Drug: Placebo; Each cohort will use placebo reconstituted in saline.; Drug: Bupivacaine Hydrochloride; 0.25% administered pre-surgery; Drug: Hydromorphone; 0.02 mg/kg IV administered intraoperatively; Drug: Fentanyl; 100 mcg IV administered intraoperatively; Drug: Acetaminophen; 1000 mg IV administered intraoperatively; Drug: Oxycodone; 5-10 mg PO administered post-surgery
Active Comparator: CA-008 10 mg (0.1 mg/mL); Cohort 2 (CA-008 10 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).	Drug: Bupivacaine Hydrochloride; 0.25% administered pre-surgery; Drug: Hydromorphone; 0.02 mg/kg IV administered intraoperatively; Drug: Fentanyl; 100 mcg IV administered intraoperatively; Drug: Acetaminophen; 1000 mg IV administered intraoperatively; Drug: Oxycodone; 5-10 mg PO administered post-surgery; Drug: CA-008 10 mg; 10 mg CA-008 reconstituted in saline.; Other Name: Vocacapsaicin
Active Comparator: CA-008 15 mg (0.15 mg/mL); Cohort 3 (CA-008 15 mg): the surgery is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).	Drug: Bupivacaine Hydrochloride; 0.25% administered pre-surgery; Drug: Hydromorphone; 0.02 mg/kg IV administered intraoperatively; Drug: Fentanyl; 100 mcg IV administered intraoperatively; Drug: Acetaminophen; 1000 mg IV administered intraoperatively; Drug: Oxycodone; 5-10 mg PO administered post-surgery; Drug: CA-008 15 mg; 15 mg CA-008 reconstituted in saline.; Other Name: Vocacapsaicin
Placebo Comparator: Placebo for Cohorts 2 and 3; Cohorts 2 & 3: Placebo comparator in each cohort is identical in appearance to the investigational product, containing the same excipients as the active comparator. The surgery for each subject is to be performed under general anesthesia supplemented by a transverse abdominis plane (TAP) block and local surgical site infiltration. Prior to the surgery, perform the TAP block as a single injection of 0.25% bupivacaine hydrochloride (HCl) 60 mL (150 mg).	Drug: Placebo; Each cohort will use placebo reconstituted in saline.; Drug: Bupivacaine Hydrochloride; 0.25% administered pre-surgery; Drug: Hydromorphone; 0.02 mg/kg IV administered intraoperatively; Drug: Fentanyl; 100 mcg IV administered intraoperatively; Drug: Acetaminophen; 1000 mg IV administered intraoperatively; Drug: Oxycodone; 5-10 mg PO administered post-surgery

Outcome Measures

Primary Outcome Measures :

1. Pain Intensity Scores at 96 Hours at Rest Using Numerical Rating Scale (NRS) [ Time Frame: 96 hours ]
   Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 96 hours

Secondary Outcome Measures :

1. Weighted Sum of Pain Intensity (SPI) Assessments = AUC of NRS Scores [ Time Frame: 0 to 96 hours ]
   Pain intensity scores (using a Numeric Rating Scale of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable) from 0 to T96 hours
2. Time to Opioid Cessation or Freedom [ Time Frame: From Surgery to Day 29 ]
   Time to the last use of opioid
3. Percent of Opioid Free Subjects [ Time Frame: 24 to 96 hours ]
   Percent of subjects who were opioid free at 24-96 hours
4. Total Opioid Consumption [ Time Frame: 0 to 96 hours ]
   The sum of daily opioid consumption (in morphine equivalents)

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria:

• Plan to undergo an elective complete abdominoplasty (C-ABD), without collateral procedure or additional surgeries.
• In the medical judgment of the investigator, be a reasonably healthy adult aged 18 - 65 years old, inclusive, and American Society of Anesthesiology (ASA) physical Class 1 or 2 at the time of randomization.
• Unless the subject has a same sex partner, he or she must either be sterile (surgically or biologically) or commit to an acceptable method of birth control while participating in the study.
• Have a body mass index ≤ 35 kg/m².
• Be willing and able to sign the informed consent form (ICF) approved by an Institutional Review Board (IRB).

Key Exclusion Criteria:

• In the opinion of the Investigator, have a concurrent painful condition that may require analgesic treatment during the study period or may confound post-surgical pain assessments.
• Have a known allergy to chili peppers, capsaicin or the components of CA-008, acetaminophen, bupivacaine, fentanyl hydromorphone or oxycodone.
• As determined by the investigator have a history or clinical manifestation of significant medical, neuropsychiatric or other condition, including a clinically significant existing arrhythmia, left bundle branch block or abnormal ECG, myocardial infarction or coronary arterial bypass graft surgery within the prior 12 months, significant abnormal clinical laboratory test value, or known bleeding abnormality that could preclude or impair study participation or interfere with study assessments.

• The following are considered disallowed medications:

  1. Be tolerant to opioids defined as those who have been receiving or have received chronic opioid therapy greater than 15 mg of oral morphine equivalents per day for greater than 3 out of 7 days per week over a one-month period within 6 months of screening.
  2. Within 1 day prior to surgery and throughout the inpatient period, be taking any capsaicin-containing products, such as dietary supplements or over-the-counter (OTC) preparations, including topical formulations, and prescription medications.
  3. Within the 7 days prior to surgery, be taking any central nervous system (CNS) active agent as an analgesic adjunct medication, such as anticonvulsants, antidepressants, benzodiazepines, sedative- hypnotics, clonidine and other central alpha-2 agents, ketamine or muscle relaxants.

  i. These drugs are permitted if prescribed for non-pain indications and the dose has been stable for at least 30 days prior to surgery.

ii. The use of benzodiazepines and the non-benzodiazepines are permitted to treat insomnia during the postoperative period.

Contacts and Locations

Locations

United States, California

Lotus Clinical Research, LLC

Pasadena, California, United States, 91105

Sponsors and Collaborators

Concentric Analgesics

Investigators

• Principal Investigator: Alina Beaton, MD; Lotus Clinical Research, LLC

  Study Documents (Full-Text)

Documents provided by Concentric Analgesics:

Study Protocol  [PDF] January 28, 2019

Statistical Analysis Plan  [PDF] April 24, 2019

More Information

• Responsible Party: Concentric Analgesics
• ClinicalTrials.gov Identifier: NCT03789318
• Other Study ID Numbers: CA-PS-204
• First Posted: December 28, 2018
• Results First Posted: January 13, 2022
• Last Update Posted: March 19, 2024
• Last Verified: March 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Pain, Postoperative; Postoperative Complications; Pathologic Processes; Pain; Neurologic Manifestations; Acetaminophen; Fentanyl; Oxycodone; Hydromorphone; Bupivacaine; Anesthetics, Local; Anesthetics; Central Nervous System Depressants; Physiological Effects of Drugs; Sensory System Agents; Peripheral Nervous System Agents; Analgesics, Opioid; Narcotics; Analgesics; Adjuvants, Anesthesia; Anesthetics, Intravenous; Anesthetics, General; Analgesics, Non-Narcotic; Antipyretics